CRON โ Cronos Group ยท catalysts, narrative & risks
Snapshot (as of Oct 2, 2026)
As of the Oct 2, 2026 close, CRON traded around $3.22โ$3.23 with a market capitalization near $1.19 billion, sitting close to the top of its 52-week range ($2.28โ$3.61) [15][17]. Trailing twelve-month (TTM) figures show a P/E near 16, TTM EPS of $0.19, TTM revenue of ~$179 million, TTM net income of ~$70 million, cash of ~$797 million, and a Total Debt/Equity ratio of just 0.12% [15]. The stock is dual-listed on NASDAQ (CRON) and the TSX (CRON), and is described by one source as Health Care / Pharmaceuticals & Cannabis, even though a separate internal universe file classifies it under consumer_staples [10][17]. The stock is up roughly 40% over the past year [5].
Recent catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ